FORM 3

UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPRO	VAL				
OMB	3235-				
Number:	0104				
Estimated average					
burden hours pei	٢				
response	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)											
1. Name and Address of Reporting					3. Issuer Name and Ticker or Trading Symbol						
Person *		Statement (Month/Day/Year)			Cellectar Biosciences, Inc. [CLRB]						
Szakacs Cameron			r)								
(Last) (First) (Middle	11/2 4	11/24/2014			4. Relationship of Reporting 5. 1				. If Amendment, Date Original		
C/O CELLECTAR									led(Mor	nth/Day/Year)	
BIOSCIENCES, INC., 3301		(Check all applicable)									
AGRICULTURE DRIVE			Director 10% Owner X Officer (give Other (specify								
(Street)				title below) below) VP of Clinical Development			6.	Indivi	dual or Joint/Group		
				L	VP of Clir	nica	i Developme	F1.		eck Applicable Line)	
MADISON, WI 53716								_X		iled by One Reporting Person led by More than One Reporting	
								Per	rson	ica by More than one resporting	
(City) (State) (Zip)		Ta	ble I -	- Non	-Derivati	ive	Securities	Benefi	cially	Owned	
1.Title of Security			2. Amount of Securities 3. 4. Natur			. Nature	re of Indirect Beneficial				
(Instr. 4)			3				wnership Ownership				
		(In	str. 4)				orm: Direct (Instr. 5)				
							direct (I)				
					(Instr. 5)						
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.											
Table II - Derivative Se	curities Ben	eficially C	Owned	(e.g.,]	puts, calls,	wai	rrants, optio	ns, conv	ertible	e securities)	
1. Title of Derivative Security					e and Amount of 4. 5.			5.		6. Nature of Indirect	
(Instr. 4) and Expiration I (Month/Day/Year)		y/Year) Derivativ			es Underlying ive Security		Conversion or Exercise Price of			Beneficial Ownership	
								Form of Derivation	-	(Instr. 5)	
	_		(Instr. 4)		4)		Derivative	Securi			
	Date Exercisable	Expiration	1				Security	Direct	-		
	Exercisable	Date	Title		unt or Numl	ber		or Indi	irect		
				of Sh	ares			(I)			
								(Instr.	5)		
Reporting Owners											
Relations Relations					onships						
Reporting Owner Name / Address Dire		Director	or 10% Owner Officer						Other		
Szakacs Cameron	ICEC DIC										

Reporting Owner Name / Address		Relationships					
		10% Owner	Officer	Other			
Szakacs Cameron C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON, WI 53716			VP of Clinical Development				

Signatures

/s/ Chad Kolean, attorney-in-fact for Cameron Szakacs	12/18/2014
**Signature of Reporting Person	Date

Explanation of Responses:

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized and designated Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The authority of Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

Dated:	16 Dec. 2014	Signed:	/s/ Cameron Szakacs	
		Print Name:	Cameron Szakacs	